146 related articles for article (PubMed ID: 15776786)
1. Focus on: biologics that affect therapeutic agents in dermatology.
Saripalli YV; Gaspari AA
J Drugs Dermatol; 2005; 4(2):233-45. PubMed ID: 15776786
[TBL] [Abstract][Full Text] [Related]
2. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
Baker DE
Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
LaDuca JR; Gaspari AA
Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor antagonists in the therapy of psoriasis.
Mössner R; Schön MP; Reich K
Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
[TBL] [Abstract][Full Text] [Related]
6. TNF- alpha inhibitors.
Jackson JM
Dermatol Ther; 2007; 20(4):251-64. PubMed ID: 17970890
[TBL] [Abstract][Full Text] [Related]
7. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
Rigby WF
Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
9. Differentiating the efficacy of tumor necrosis factor inhibitors.
Haraoui B
J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
11. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
[TBL] [Abstract][Full Text] [Related]
12. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
Breedveld FC
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
[TBL] [Abstract][Full Text] [Related]
13. Innovative uses of tumor necrosis factor alpha inhibitors.
Mazza J; Rossi A; Weinberg JM
Dermatol Clin; 2010 Jul; 28(3):559-75. PubMed ID: 20510765
[TBL] [Abstract][Full Text] [Related]
14. [Value of anti-TNF-alpha molecules in inflammatory and infectious diseases].
Fautrel B; Cherin P
Rev Med Interne; 2000 Oct; 21(10):872-88. PubMed ID: 11075396
[TBL] [Abstract][Full Text] [Related]
15. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
[TBL] [Abstract][Full Text] [Related]
16. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
17. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
18. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
Tanaka Y
Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.
Silva LC; Ortigosa LC; Benard G
Immunotherapy; 2010 Nov; 2(6):817-33. PubMed ID: 21091114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
